The findings on tumor mutational burden (TMB) may fill a gap in biomarkers for patients who have non–small cell lung cancer (NSCLC). The findings could make it easier for clinicians to personalize ...
A recent study found that patients with advanced solid cancers with high tumor mutational burden (TMB) saw improved outcomes on immune checkpoint inhibitors (ICIs) compared with patients who had ...
Trusted Media Brands is working to sell audiences across multiple verticals, using first-party data and AI to help distill ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results